2. Search Result
Search Result
Results for "

neurodegenerative diseases and breast cancer

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

3

Peptides

3

Natural
Products

1

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-113110
    Cysteinylglycine

    		Endogenous Metabolite Neurological Disease Cancer
    Cysteinylglycine is a dipeptide produced by the decomposition of extracellular glutathione catalyzed by γ-glutamyl transpeptidase. Cysteinylglycine is a highly reactive metabolite. Cysteinylglycine is currently mainly used in neurodegenerative diseases and breast cancer research .
    Cysteinylglycine
  • HY-P10928
    BCY17901 TFA

    		Transferrin Receptor Neurological Disease Cancer
    BCY17901 TFA is a potent irreversible transferrin receptor 1 (TfR1) inhibitor (Ki=12 nM). BCY17901 TFA inhibits TfR1-mediated endocytosis and iron transport, and suppresses the proliferation of tumor cells dependent on iron metabolism. BCY17901 TFA can be used in the research of solid tumors (such as breast cancer, glioblastoma) and neurodegenerative diseases .
    BCY17901 TFA
  • HY-137441
    Icapamespib
    1 Publications Verification

    PU-HZ151

    		 HSP Neurological Disease Cancer
    Icapamespib (PU-HZ151; PU-AD) is a selective, orally active inhibitor of Epichaperomes assembled by HSP90 with slow dissociation kinetics. Icapamespib can cross the blood-brain barrier (BBB) ??and induce epichaperome disassembly by non-covalently binding to HSP90, restoring the normal protein-protein interaction network. Icapamespib can specifically disrupt disease-related abnormal protein interaction networks, reduce neurotoxic protein aggregation and tumor cell survival signals. Icapamespib can be used in the research of neurodegenerative diseases such as Alzheimer's disease, as well as cancers such as glioblastoma and metastatic breast cancer .
    Icapamespib
  • HY-137441A
    Icapamespib hydrochloride
    1 Publications Verification

    PU-HZ151 hydrochloride

    		 HSP Neurological Disease Cancer
    Icapamespib (PU-HZ151; PU-AD) hydrochloride is a selective, orally active inhibitor of Epichaperomes assembled by HSP90 with slow dissociation kinetics. Icapamespib hydrochloride can cross the blood-brain barrier (BBB) ??and induce epichaperome disassembly by non-covalently binding to HSP90, restoring the normal protein-protein interaction network. Icapamespib hydrochloride can specifically disrupt disease-related abnormal protein interaction networks, reduce neurotoxic protein aggregation and tumor cell survival signals. Icapamespib hydrochloride can be used in the research of neurodegenerative diseases such as Alzheimer's disease, as well as cancers such as glioblastoma and metastatic breast cancer .
    Icapamespib hydrochloride
  • HY-139066
    Punicic acid

    Trichosanic acid

    		 TNF Receptor GLUT Proteasome Tau Protein PKC Neurological Disease Metabolic Disease Inflammation/Immunology
    Punicic acid is a bioactive compound of pomegranate seed oil. Punicic acid is an isomer of conjugated α-linolenic acid and ω-5 polyunsaturated fatty acids. Punicic acid has anti-inflammatory and antioxidant activities and can inhibit the expression of inflammatory mediators such as tumor necrosis factor α (TNF-α). Punicic acid can also reduce the formation of β-amyloid deposits and hyperphosphorylation of tau by increasing the expression of GLUT4 protein and inhibiting the overactivation of calpain, and is used to prevent and treat neurodegenerative diseases. In addition, punicic acid also has breast cancer inhibitor properties that depend on lipid peroxidation and PKC pathways .
    Punicic acid
  • HY-113110R
    Cysteinylglycine (Standard)

    		Endogenous Metabolite Neurological Disease Cancer
    Cysteinylglycine (Standard) is the analytical standard of Cysteinylglycine. This product is intended for research and analytical applications. Cysteinylglycine is a dipeptide produced by the decomposition of extracellular glutathione catalyzed by γ-glutamyl transpeptidase. Cysteinylglycine is a highly reactive metabolite. Cysteinylglycine is currently mainly used in neurodegenerative diseases and breast cancer research .
    Cysteinylglycine (Standard)
  • HY-175328
    LIBX-A403

    		Ferroptosis Neurological Disease Cancer
    LIBX-A403 (Compound 21) is a highly selective acyl-CoA synthetase long-chain family member 4 (ACSL4) inhibitor (IC50=0.049 μM). LIBX-A403 blocks ACSL4-mediated ferroptosis-promoting phospholipid remodeling. LIBX-A403 is promising for research of cancers (e.g., triple-negative breast cancer) and neurodegenerative diseases (e.g., Parkinson’s disease) .
    LIBX-A403
  • HY-P10928A
    BCY17901

    		Transferrin Receptor Neurological Disease Cancer
    BCY17901 is a potent irreversible transferrin receptor 1 (TfR1) inhibitor (Ki=12 nM). BCY17901 inhibits TfR1-mediated endocytosis and iron transport, and suppresses the proliferation of tumor cells dependent on iron metabolism. BCY17901 can be used in the research of solid tumors (such as breast cancer, glioblastoma) and neurodegenerative diseases .
    BCY17901
  • HY-175453
    MRT-23227

    		Molecular Glues Neurological Disease Cancer
    MRT-23227 is a molecular glue degrader that targets cereblon (CRBN). MRT-23227 forms a ternary complex with CRBN and G3BP2, activating the ubiquitin-proteasome system, leading to G3BP2 degradation. MRT-23227 has potential applications in the research of G3BP2-related cancers (such as breast and lung cancer) and neurodegenerative diseases .
    MRT-23227
  • HY-174329
    mrt-5702D

    		Molecular Glues Neurological Disease Cancer
    mrt-5702D is a molecular glue degrader targeting cereblon (CRBN). mrt-5702D forms a CRBN-MRT-5702D-G3BP2 ternary complex to activate the ubiquitin-proteasome system for G3BP2 degradation. mrt-5702D is promising for research of G3BP2-related cancers (e.g., breast cancer, lung cancer) and neurodegenerative diseases .
    mrt-5702D

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: